What is the appropriate evaluation and management plan for a patient presenting with anxiety symptoms at an initial primary care visit?

Initial Primary Care Visit for Anxiety Symptoms

For a patient presenting with anxiety symptoms at an initial primary care visit, begin with validated screening using the GAD-7 scale, assess for medical causes and safety concerns, then implement a stepped-care approach based on symptom severity: mild symptoms warrant education and active monitoring, moderate symptoms require low-intensity interventions (self-help CBT or SSRIs), and moderate-to-severe/severe symptoms necessitate referral to mental health specialists for combined pharmacologic and psychological treatment. 1, 2

Screening and Assessment

Initial Screening

• Use the GAD-7 (Generalized Anxiety Disorder-7) scale as your primary screening tool 1, 3

  • Score 0-4: None/mild symptomatology
  • Score 5-9: Moderate symptomatology
  • Score 10-14: Moderate to severe symptomatology
  • Score 15-21: Severe symptomatology

• The GAD-7 is specifically validated for primary care settings and is brief enough for routine use 3

• For social anxiety specifically, consider the Mini-SPIN (3 items), which is 89% sensitive and 90% specific with a cutoff of ≥6 points 3

Comprehensive Assessment Components

Identify specific anxiety symptoms:

• Panic attacks, trembling, sweating, tachypnea, tachycardia, palpitations, sweaty palms
• Excessive worry or concerns disproportionate to actual risk
• Fatigue, sleep disturbances, irritability, concentration difficulties 1

Rule out medical and substance-induced causes FIRST:

• Uncontrolled pain or other physical symptoms
• Delirium (infection, electrolyte imbalance)
• Substance use or withdrawal
• Thyroid disorders, cardiac conditions 1

Assess safety immediately:

• Risk of harm to self or others requires emergency referral to mental health professional, one-to-one observation, and harm-reduction interventions 1

Identify risk factors and history:

• Family history of anxiety disorders
• Personal history of anxiety with or without prior treatment
• Comorbid psychiatric disorders (especially depression—50-60% comorbidity)
• Alcohol or substance use/abuse
• Presence of other chronic illnesses
• Level of functional impairment in daily activities 1

Treatment Algorithm Based on Severity

Mild Symptoms (GAD-7: 0-4)

• Education and active monitoring 1
• Provide information about anxiety, coping strategies, and when to seek further help
• Reassess monthly or as needed
• No immediate pharmacologic intervention required

Moderate Symptoms (GAD-7: 5-9)

Low-intensity interventions (choose based on patient preference and availability):

• Nonfacilitated or guided self-help based on CBT, including behavioral activation and problem solving 1
• Brief CBT in primary care if embedded behavioral health clinician available 2
• Pharmacologic treatment as appropriate:
  • First-line: SSRIs or SNRIs (selective serotonin-norepinephrine reuptake inhibitors) 1, 2
  • Choice informed by side effect profiles, drug interactions, patient age, and preference
  • Avoid benzodiazepines due to cognitive impairment, abuse potential, and dependence risk—use only short-term if absolutely necessary 1, 2

Moderate-to-Severe/Severe Symptoms (GAD-7: 10-21)

Refer to psychiatrist, psychologist, or equivalently trained mental health professional for:

• Diagnostic confirmation using DSM-5 criteria before initiating treatment 1

• Individual psychological therapy delivered by licensed professionals using evidence-based treatment manuals including:

  • Cognitive change techniques
  • Behavioral activation
  • Biobehavioral strategies
  • Education and relaxation strategies
  • Relapse prevention (important as GAD is often chronic) 1

• Pharmacologic treatment:

  • Physician-prescribed SSRIs or anxiolytics
  • Monitor regularly for adherence, side effects, and adverse events 1

• Consider Collaborative Care Management model involving primary care clinician, consulting psychiatrist, and care manager who monitors progress 2, 4

Critical Pitfalls to Avoid

Benzodiazepine overuse: These medications carry increased risk of abuse, dependence, and cognitive impairment. Use should be time-limited per psychiatric guidelines, primarily for short-term symptom relief while awaiting SSRI/SNRI effect 1, 2

Missing medical causes: Always rule out thyroid disease, cardiac conditions, substance use, pain, and delirium before attributing symptoms solely to anxiety disorder 1

Ignoring comorbid depression: 50-60% of patients with anxiety have comorbid depression. Screen for both and typically treat depression first when both present 1

Poor follow-through: Patients with anxiety commonly avoid threatening stimuli and may not follow through on referrals. This requires proactive monthly follow-up until symptoms subside 1

Follow-Up and Monitoring

Monthly reassessment until symptoms subside:

• Assess compliance with psychological/psychosocial referrals and satisfaction
• Monitor pharmacologic treatment adherence, side effects, and symptom relief
• After 8 weeks: If poor symptom reduction despite good compliance, alter treatment (add intervention, change medication, or refer to individual therapy if group therapy unsuccessful) 1

Consider medication tapering when:

• Anxiety symptoms are under control
• Primary environmental sources of anxiety are no longer present
• Longer tapering periods necessary for benzodiazepines 1

Patient Education

Provide verbal and written information about:

• Nature of anxiety and its symptoms
• Treatment options and expected timeline for improvement
• Specific symptoms or worsening that warrant immediate contact
• Importance of treatment adherence despite anxiety-driven avoidance 1

Note on evidence limitations: The available guidelines are primarily from oncology populations [1-1], but the stepped-care approach, screening tools, and treatment principles are generalizable to primary care settings, as confirmed by primary care-specific research [3-4]. The most recent comprehensive guidance for general primary care comes from 2026 research emphasizing screening for patients under 65, CBT as first-line behavioral treatment, and SSRIs/SNRIs as first-line pharmacotherapy 2.